RheumaGen
DENVER, CO · Biotechnology · 6 employees
RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure common autoimmune diseases at their source. RheumaGen focuses on editing the human leukocyte antigen (HLA), or “immune gene,” to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado.
Funding history
- Series series a — $15.0M — Jan 2025
- Series seed — $700K — Apr 2024
- Series seed — $4.9M — Apr 2024
- Series seed — $300K — May 2023
Recent signals
- Jan 09, 2025: Raised $15.0M in Series series a
- Apr 17, 2024: Raised $700K in Series seed
- Apr 17, 2024: Raised $4.9M in Series seed
- May 26, 2023: Raised $300K in Series seed
See plans & pricing → Track RheumaGen’s funding, hiring, and signals — with verified contacts — on Fundz.